Your session is about to expire
← Back to Search
Study Summary
This trial is testing whether a person's tumor biomarker status can predict if they are eligible for a Roche clinical trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Non-Small Cell Lung Cancer (NSCLC)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Is this research study enrolling new participants at present?
"Yes, this research study is looking for individuals to participate and is currently enrolling patients. The trial was first announced on July 22nd, 2022 and the most recent update was November 1st, 2022."
What is the size of the sample population in this research project?
"The sponsor, Hoffmann-La Roche, needs to recruit 15000 eligible patients in order to successfully carry out the trial. The clinical study will be conducted at various locations, including Thompson Cancer Survival Center in Knoxville, Tennessee and Oncology & Hematology Associates of Southwest Virginia, Inc in Blacksburg, Virginia."
In how many different hospitals is this medical study being run today?
"Currently, this 18 different hospitals are running this trial. Some of the locations include Knoxville, Blacksburg and Tucson. To alleviate some stress, patients are encouraged to pick a location that is closest to them."
Is it legal to market and sell this drug in the United States?
"The safety of this novel treatment falls in the middle of our 1-to-3 scale at a 2. This is due to the lack of efficacy data, as this is only a Phase 2 trial."
Share this study with friends
Copy Link
Messenger